Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer

Korean J Intern Med. 2014 Nov;29(6):830-3. doi: 10.3904/kjim.2014.29.6.830. Epub 2014 Oct 31.

Authors

Jeong Uk Lim¹, In Sook Woo¹, Yun Hwa Jung¹, Jae Ho Byeon¹, Chan Kwon Park², Tae Jung Kim³, Hyo Rim Kim⁴

Affiliations

¹ Division of Hematology and Oncology, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
² Division of Pulmonology, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
³ Department of Hospital Pathology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
⁴ Department of Radiology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

No abstract available

Keywords: Acquired resistance; Erlotinib; Neuroendocrine.

Publication types

Case Reports
Letter

MeSH terms

Adenocarcinoma / chemistry
Adenocarcinoma / drug therapy*
Adenocarcinoma / secondary
Adenocarcinoma of Lung
Adult
Antineoplastic Agents / therapeutic use*
Biomarkers, Tumor / analysis
Biopsy
Carcinoma, Large Cell / chemistry
Carcinoma, Large Cell / pathology*
Carcinoma, Neuroendocrine / chemistry
Carcinoma, Neuroendocrine / pathology*
Carcinoma, Non-Small-Cell Lung / chemistry
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / secondary
Drug Resistance, Neoplasm*
Erlotinib Hydrochloride
Humans
Lung Neoplasms / chemistry
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Magnetic Resonance Imaging
Male
Protein Kinase Inhibitors / therapeutic use*
Quinazolines / therapeutic use*
Tomography, X-Ray Computed
Treatment Outcome

Substances

Antineoplastic Agents
Biomarkers, Tumor
Protein Kinase Inhibitors
Quinazolines
Erlotinib Hydrochloride